Wednesday, September 16, 2020

Remdesivir Market Report 2020 – Covering Impact of COVID-19, Developments, SWOT Analysis by Global Top Companies – Hainan Haiyao, EVA PHARM, Cipla, Mylan

“Remdesivir Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020–2030” suggests that global remdesivir market is expected to witness substantial CAGR from 2020 to 2030.

The factors contributing to the growth of remdesivir market include, rising number of coronavirus disease (COVID-19) and increasing government initiatives. The advantages of remdesivir observed during the trails such as shortened time of recovery by an average of four days is another key factor driving its demand. Agreements signed by Gilead with generic manufacturers to deliver treatment at a substantially lower cost in the developing countries is also anticipated to boost the market growth during the forecast period. However, the possibility of shortage of the drug and the concerns related to the safety and efficacy of remdesivir amongst the patient population are some factors that are likely to hinder the market growth to a certain extent.

Major Key Players of the Remdesivir Market are:
Gilead Sciences, Inc., BrightGene Bio-Medical Technology Co.,Ltd., Hainan Haiyao Co., Ltd., EVA PHARM, Cipla Inc., Mylan N.V., Hetero, Ferozsons Laboratories, Zydus Cadila, Dr. Reddy’s Laboratories Ltd. and Beximco Pharmaceuticals Ltd., among others.

Read More @ https://www.medgadget.com/2020/08/remdesivir-market-report-2020-covering-impact-of-covid-19-developments-swot-analysis-by-global-top-companies-hainan-haiyao-eva-pharm-cipla-mylan.html



No comments:

Post a Comment